Drug
Hrs 5635
Hrs 5635: highest development phase Phase 3, developed by Fujian Shengdi Pharmaceutical Co., Ltd.. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Fujian Shengdi Pharmaceutical Co., Ltd.
Trials
| Drug | Phase | Indication |
|---|---|---|
| HRS-5635 Injection NCT07606950 | Phase 3 | Nucleos(t)Ide Analogue-suppressed HBeAg-negative Patients With Chronic Hepatitis B |
Latest
No recent events.
Follow Hrs 5635 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.